Your browser doesn't support javascript.
loading
Pathogenic ATM Mutations in Cancer and a Genetic Basis for Radiotherapeutic Efficacy.
Pitter, Kenneth L; Casey, Dana L; Lu, Yue C; Hannum, Margaret; Zhang, Zhigang; Song, Xinmao; Pecorari, Isabella; McMillan, Biko; Ma, Jennifer; Samstein, Robert M; Pei, Isaac X; Khan, Atif J; Braunstein, Lior Z; Morris, Luc G T; Barker, Christopher A; Rimner, Andreas; Alektiar, Kaled M; Romesser, Paul B; Crane, Christopher H; Yahalom, Joachim; Zelefsky, Michael J; Scher, Howard I; Bernstein, Jonine L; Mandelker, Diana L; Weigelt, Britta; Reis-Filho, Jorge S; Lee, Nancy Y; Powell, Simon N; Chan, Timothy A; Riaz, Nadeem; Setton, Jeremy.
Afiliação
  • Pitter KL; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Casey DL; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lu YC; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Hannum M; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zhang Z; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Song X; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pecorari I; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • McMillan B; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Ma J; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Samstein RM; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Pei IX; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Khan AJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Braunstein LZ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Morris LGT; Department of Surgery, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Barker CA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Rimner A; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Alektiar KM; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Romesser PB; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Crane CH; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Yahalom J; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Zelefsky MJ; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Scher HI; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Bernstein JL; Department of Epidemiology & Biostatistics, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Mandelker DL; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Weigelt B; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Reis-Filho JS; Department of Pathology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Lee NY; Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Powell SN; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Chan TA; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
  • Riaz N; Molecular Biology Program, Sloan Kettering Institute, New York, NY, USA.
  • Setton J; Department of Radiation Oncology, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
J Natl Cancer Inst ; 113(3): 266-273, 2021 03 01.
Article em En | MEDLINE | ID: mdl-32726432
ABSTRACT

BACKGROUND:

Radiation therapy is one of the most commonly used cancer therapeutics but genetic determinants of clinical benefit are poorly characterized. Pathogenic germline variants in ATM are known to cause ataxia-telangiectasia, a rare hereditary syndrome notable for marked radiosensitivity. In contrast, somatic inactivation of ATM is a common event in a wide variety of cancers, but its clinical actionability remains obscure.

METHODS:

We analyzed 20 107 consecutively treated advanced cancer patients who underwent targeted genomic sequencing as part of an institutional genomic profiling initiative and identified 1085 harboring a somatic or germline ATM mutation, including 357 who received radiotherapy (RT). Outcomes of irradiated tumors harboring ATM loss-of-function (LoF) mutations were compared with those harboring variants of unknown significance. All statistical tests were 2-sided.

RESULTS:

Among 357 pan-cancer patients who received 727 courses of RT, genetic inactivation of ATM was associated with improved radiotherapeutic efficacy. The 2-year cumulative incidence of irradiated tumor progression was 13.2% vs 27.5% for tumors harboring an ATM LoF vs variant of unknown significance allele, respectively (hazard ratio [HR] = 0.51, 95% confidence interval [CI] = 0.34 to 0.77, P = .001). The greatest clinical benefit was seen in tumors harboring biallelic ATM inactivation (HR = 0.19, 95% CI = 0.06 to 0.60, P = .005), with statistically significant benefit also observed in tumors with monoallelic ATM inactivation (HR = 0.57, 95% CI = 0.35 to 0.92, P = .02). Notably, ATM LoF was highly predictive of outcome in TP53 wild-type tumors but not among TP53-mutant tumors.

CONCLUSIONS:

We demonstrate that somatic ATM inactivation is associated with markedly improved tumor control following RT. The identification of a radio-sensitive tumor phenotype across multiple cancer types offers potential clinical opportunities for genomically guided RT.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutação de Sentido Incorreto / Proteínas Mutadas de Ataxia Telangiectasia / Neoplasias Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Mutação de Sentido Incorreto / Proteínas Mutadas de Ataxia Telangiectasia / Neoplasias Tipo de estudo: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limite: Adolescent / Adult / Aged / Aged80 / Child / Female / Humans / Male / Middle aged Idioma: En Revista: J Natl Cancer Inst Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos